Clinical case of generalized amyloidosis (ATTR-amyloidosis) with a progressive course of chronic heart failure. Case report
- Authors: Golubovskaya D.P.1, Dren’ E.V.1, Yurkina A.V.1, Pecherina T.B.1, Barbarash O.L.1
-
Affiliations:
- Research Institute of Complex Problems of Cardiovascular Diseases
- Issue: Vol 96, No 7 (2024): VARIO
- Pages: 695-700
- Section: Clinical notes
- URL: https://journals.rcsi.science/0040-3660/article/view/262140
- DOI: https://doi.org/10.26442/00403660.2024.07.202784
- ID: 262140
Cite item
Full Text
Abstract
Despite the presence of various signs of cardiac amyloidosis ("red flags"), the introduction into routine practice of new non-invasive diagnostic methods (Speckle Tracking technology using echocardiography, myocardial scintigraphy with technetium pyrophosphate, genetic testing, screening for free light chains of immunoglobulins to exclude AL-amyloidosis), which have high specificity and sensitivity, transthyretinic (ATTR) cardiomyopathy is still a difficult to diagnose disease, especially in the early stages when treatment is most effective. The article presents a clinical case of ATTR-amyloidosis with predominant heart damage, manifested by severe diastolic heart failure resistant to treatment. The timing, from the moment of the first episode of decompensation of heart failure to death, is 4 months, which confirms the rapid progression of severe biventricular dysfunction of the heart. Despite the presence of cardiac and extracardial "red flags" of ATTR-amyloidosis in the patient, the diagnosis was established at autopsy. The paper analyzes possible errors of early diagnosis at the outpatient and inpatient stages of patient management.
Full Text
##article.viewOnOriginalSite##About the authors
Daria P. Golubovskaya
Research Institute of Complex Problems of Cardiovascular Diseases
Author for correspondence.
Email: dasha250695k@mail.ru
ORCID iD: 0000-0002-3922-009X
мл. науч. сотр. лаб. фиброгенеза миокарда
Russian Federation, KemerovoElena V. Dren’
Research Institute of Complex Problems of Cardiovascular Diseases
Email: dasha250695k@mail.ru
ORCID iD: 0000-0002-5469-7638
очный аспирант по специальности «кардиология», лаборант-исследователь лаб. фиброгенеза миокарда
Russian Federation, KemerovoAnastasia V. Yurkina
Research Institute of Complex Problems of Cardiovascular Diseases
Email: dasha250695k@mail.ru
ORCID iD: 0009-0001-9761-9197
мл. науч. сотр. лаб. фиброгенеза миокарда
Russian Federation, KemerovoTamara B. Pecherina
Research Institute of Complex Problems of Cardiovascular Diseases
Email: dasha250695k@mail.ru
ORCID iD: 0000-0002-4771-484X
д-р мед. наук, доц., зав. лаб. фиброгенеза миокарда
Russian Federation, KemerovoOlga L. Barbarash
Research Institute of Complex Problems of Cardiovascular Diseases
Email: dasha250695k@mail.ru
ORCID iD: 0000-0002-4642-3610
акад. РАН, д-р мед. наук, проф., директор
Russian Federation, KemerovoReferences
- Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types. Circulation. 2009;120(13):1203-12. doi: 10.1161/CIRCULATIONAHA.108.843334
- Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019;12(9):e006075. doi: 10.1161/CIRCHEARTFAILURE.119.006075
- Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007-16. doi: 10.1056/NEJMoa1805689
- Lahuerta Pueyo C, Aibar Arregui MÁ, Gracia Gutierrez A, et al. Estimating the prevalence of allelic variants in the transthyretin gene by analysing large-scale sequencing data. Eur J Hum Genet. 2019;27(5):783-91. doi: 10.1038/s41431-019-0337-1
- Резник Е.В., Степанова E.A., Нгуен Т., и др. Ретроспективный анализ поражения сердечно-сосудистой системы у больных системным амилоидозом. Кардиоваскулярная терапия и профилактика. 2021;20(1):2496 [Reznik EV, Stepanova EA, Nguyen T, et al. Retrospective analysis of cardiovascular involvement in patients with systemic amyloidosis. Cardiovascular Therapy and Prevention. 2021;20(1):2496 (in Russian)]. doi: 10.15829/1728-8800-2021-2496
- Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: A population-based autopsy study. Ann Med. 2008;40(3):232-9. doi: 10.1080/07853890701842988
- Rowczenio D, Quarta CC, Fontana M, et al. Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience. Hum Mutat. 2019;40(1):90-6. doi: 10.1002/humu.23669
- Окунев И.М., Кочергина А.М., Кашталап В.В. Хроническая и острая декомпенсированная сердечная недостаточность: актуальные вопросы. Комплексные проблемы сердечно-сосудистых заболеваний. 2022;11(2):184-95 [Okunev IM, Kochergina AM, Kashtalap VV. Chronic and acute decompensated heart failure: Topical issues. Complex Issues of Cardiovascular Diseases. 2022;11(2):184-95 (in Russian)]. doi: 10.17802/2306-1278-2022-11-2-184-195
- Терещенко С.Н., Жиров И.В., Моисеева О.М., и др. Практические рекомендации по диагностике транстиретиновой амилоидной кардиомиопатии (ATTR-КМП или транстиретинового амилоидоза сердца). Терапевтический архив. 2022;94(4):584-95 [Tereshchenko SN, Zhirov IV, Moiseeva OM, et al. Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis). Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(4):584-95 (in Russian)]. doi: 10.26442/00403660.2022.04.201465
- Резник Е.В., Нгуен Т.Л., Степанова Е.А., и др. Амилоидоз сердца: взгляд терапевта и кардиолога. Архивъ внутренней медицины. 2020;10(6):430-57 [Reznik EV, Nguyen TL, Stepanova EA, et al. Cardiac amyloidosis: Internist and cardiologist insight. The Russian Archives of Internal Medicine. 2020;10(6):430-57 (in Russian)]. doi: 10.20514/2226-6704-2020-10-6-430-457
Supplementary files
